Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYSYME trial of allogeneic adipose-derived mesenchymal stromal cells for Stevens-Johnson syndrome/toxic epidermal necrolysis
2024-516404-42-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic adipose-derived mesenchymal stromal cells in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Safety and Complete or almost complete re-epithelialization at Day 7. Planned start Apr 2024; status: authorised.
02
Drugs
allogeneic adipose-derived mesenchymal stromal cells
03
Conditions
Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on 2024-516404-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516404-42-00.